Eutropoflavin

Eutropoflavin (4'-DMA-7,8-DHF) is a synthetic flavone that mimics the action of BDNF, the brain's main growth factor for neurons. It's a more potent, longer-acting cousin of 7,8-dihydroxyflavone (the original BDNF mimetic), made by adding a dimethylamino group to the parent molecule. People take it for stubborn low mood, mental fog, slow recovery from burnout, or memory issues, with the working hypothesis that it nudges hippocampal neurogenesis and synaptic plasticity in the same direction as

NSI-189.

Deep-dive

BDNF (brain-derived neurotrophic factor) is the protein your brain uses to grow new neurons, build and maintain synapses, and recover from stress. Low BDNF tracks with depression, cognitive aging, and neurodegenerative disease. The problem is that BDNF itself is a large protein that doesn't cross the blood-brain barrier and has a short half-life, so injecting it isn't practical. The hunt for small molecules that mimic BDNF by activating its main receptor (TrkB) has been the BDNF field for two decades.

Origin. In 2010, Keqiang Ye's lab at Emory identified 7,8-dihydroxyflavone (7,8-DHF) as a TrkB agonist that crosses the blood-brain barrier and produces neuroprotective effects in stroke and Parkinson's animal models. Later that year, the same group published a structure-activity optimisation paper describing eutropoflavin, 4'-dimethylamino-7,8-dihydroxyflavone, the most potent of the 7,8-DHF derivatives they synthesised. The Russian framing some people use is misleading. The science is American and peer-reviewed. Russia is where the compound is listed on the AIPSIN reference database and where most of the gray-market supply chain runs.

Mechanism. Eutropoflavin and 7,8-DHF are thought to bind the extracellular domain of TrkB, the receptor that BDNF binds, triggering its dimerisation and autophosphorylation. That kicks off the same downstream cascades BDNF would activate: MAPK, PI3K-Akt, and PLCγ1. Akt and MAPK in particular are the proximal drivers of neuronal survival, synaptic plasticity, and the chronic gene-expression changes that produce new neurons in the hippocampus.

In the Emory comparison study, eutropoflavin activated Akt more robustly than 7,8-DHF at low concentrations (10-50 nM), and in mouse brain it produced TrkB phosphorylation that peaked at 4 hours and partially decayed at 8-16 hours, compared to 1-2 hour peak for 7,8-DHF. This is the practical reason people prefer eutropoflavin over 7,8-DHF: longer duration of action at lower doses.

Anti-apoptotic and neuroprotective. In rat cortical neurons exposed to glutamate (a model of excitotoxic cell death), eutropoflavin blocked caspase-3 activation at 10 nM where 7,8-DHF needed 50 nM. In mice, oral dosing protected hippocampal neurons from kainic-acid-induced death in a TrkB-dependent manner (the protection disappeared when TrkB was selectively inhibited). In a Huntington's disease mouse model, 5 mg/kg twice daily improved motor function and extended survival.

Neurogenesis and antidepressant effect. This is the part that drives most of the human interest. After 21 days of oral dosing at 5 mg/kg, eutropoflavin and 7,8-DHF both increased the number of newly-born cells in the dentate gyrus of mice and reduced immobility in the forced swim test, a standard antidepressant screen. The antidepressant effect was completely blocked when TrkB was inhibited, supporting the idea that the mood effect runs through the TrkB pathway rather than off-target receptors. This mirrors how chronic SSRIs eventually drive hippocampal neurogenesis as the slow, structural piece of their antidepressant action. The compound is essentially trying to do that same structural piece directly.

The important caveat. Starting in 2017, several independent groups published evidence that 7,8-DHF and its flavone analogs may not be direct TrkB agonists in the strict pharmacological sense. The downstream biology (Akt activation, neuroprotection, neurogenesis, antidepressant effects in animals) is real and replicates, but the receptor-binding story may be cleaner in marketing material than it is in fact. The compound likely produces its effects through some combination of indirect TrkB potentiation, antioxidant activity (the catechol structure is a potent free-radical scavenger), and possibly other targets that haven't been fully mapped. From a user perspective this changes very little, the in vivo effects in rodents stand, but it does matter for translating the data to humans and for thinking about which other pathways might be involved.

Pharmacokinetics. Bioavailability and half-life in humans are unknown. 7,8-DHF in mice has roughly 5% oral bioavailability and a half-life under 30 minutes, which is why prodrug versions like R13 are being developed for Alzheimer's. Eutropoflavin appears to have improved duration based on the brain TrkB activation curves but no formal human PK study exists. This is one of the larger unknowns. Subjective reports of activity from oral dosing suggest meaningful brain exposure but plasma levels and metabolites have not been characterised in people.

Comparison to other compounds in this space.

NSI-189 works through a different and still-unidentified mechanism but converges on the same endpoint of hippocampal neurogenesis and has actual human Phase 2 data, which is a non-trivial advantage.

Bromantane works via gene-expression upregulation of dopamine synthesis enzymes, a different lever for the same general problem of low motivation and stuck mood. If you're choosing between them, NSI-189 has the most direct human evidence for cognition and mood, bromantane has the most for fatigue and motivation with weeks of carry-over, and eutropoflavin is the most experimental of the three.

Women. The published rodent studies used male C57BL/6J mice almost exclusively, including all the Emory antidepressant and neurogenesis work. There is no female-specific data on eutropoflavin. Some practical inferences are reasonable. BDNF and TrkB signalling is upregulated by oestrogen, so the same intervention may have a different effect across the menstrual cycle and across life stages, with potentially more headroom in low-oestrogen states (late luteal, perimenopause, postmenopause) where BDNF tone tends to be lower. Hippocampal volume loss with chronic stress and depression is, if anything, more pronounced in women, which means the structural target eutropoflavin aims at is at least as relevant. Skip in pregnancy and breastfeeding. There is no safety data.

Older adults. No data. Age-related decline in BDNF is one of the more consistent findings in cognitive aging, so the rationale is there, but whether oral eutropoflavin actually reaches and acts on the aged hippocampus the way it does in young mice is unknown. Older adults also tend to be on more polypharmacy and have less metabolic reserve for a research chemical with thin human data.

Limitations of the evidence in one place. No human trials of any kind. All efficacy data is rodent. Most of it comes from a single lab. The receptor-binding mechanism has been credibly challenged. Oral bioavailability and human PK are uncharacterised. Long-term safety in any species beyond a few months is not established. Sourcing is unregulated and product purity varies. Anyone using it is running their own n=1 on top of one of the more interesting but also one of the less mature areas of neuropharmacology.

Dosage:

• Typical oral dose: 20-50 mg once daily, taken in the morning. There is no human dose-response data, the range comes from rodent studies scaled down using standard human-equivalent dose conversions and refined by community reporting. Most people land between 25 and 40 mg

• Higher doses (75-100 mg+): sometimes reported but not better. The parent compound has an inverted-U response curve in animal studies, with higher concentrations producing less Akt activation, not more. There's no reason to think eutropoflavin behaves differently

• Timing: morning. The duration of TrkB activation in rodents is 8-16 hours and the activating effect on mood and cognition can interfere with sleep if dosed late

• With or without food: unknown for eutropoflavin specifically. The parent flavone is poorly water-soluble and absorption may improve modestly with fat. Some users dose with a small amount of olive oil or a fat-containing meal

• Course length: the meaningful animal studies ran 21 days of daily dosing to produce neurogenesis and antidepressant effects. A 3-4 week course followed by a 2-4 week break is the most common pattern. There is no evidence supporting indefinite daily use and no long-term safety data

• Stacking: community reports of stacking with
  
  NSI-189, lithium orotate, or omega-3 are common but unstudied. Avoid stacking with multiple compounds that are themselves research chemicals at the same time, you lose the ability to attribute effects or side effects. Don't stack with MAOIs or strongly serotonergic drugs, the interaction profile is uncharacterised

• Women considering it for cycle-linked mood symptoms may want to time courses to the late luteal phase or use it across a full cycle and reassess. There is no evidence-based protocol for this, only the mechanistic rationale that BDNF tone runs lower when oestrogen is low

Here's what you can expect:

Side effects & risks:

• No human safety data. The longest controlled rodent study ran 3 weeks at 5 mg/kg and showed no organ toxicity, blood-count abnormalities, or weight loss. Beyond that, nothing systematic exists in any species. This is the dominant risk

• Headache, mild dizziness, or fatigue are the most commonly reported subjective side effects from users, generally mild and self-limiting

• Activation effects (anxiety, restlessness, irritability, insomnia) in the first 1-2 weeks are reported by a subset of users. Usually resolves with dose reduction or stopping. If insomnia is the issue, dose earlier in the day

• Catechol stability. The 7,8-dihydroxy group that drives the activity is a catechol, which is chemically reactive and oxidises in air and in solution. This affects shelf life and may affect what's actually in any given bottle of research-grade powder. Storage in the original container, away from heat and light, matters more than for most supplements

• Drug interactions are uncharacterised. The compound has not been formally tested for CYP enzyme interactions. Theoretical concerns exist for MAOIs (avoid), SSRIs and SNRIs (caution, no data on the combination), and any drug with a narrow therapeutic window. Caffeine and standard nootropics seem to be tolerated based on user reports but this is not a substitute for actual interaction data

• Pregnancy and breastfeeding: avoid. No safety data, and BDNF/TrkB signalling is critical in fetal and neonatal brain development

• Active or recent cancer: caution. BDNF/TrkB signalling is involved in some tumour biology (particularly neuroblastoma and certain breast cancers). The clinical relevance of this for a small-molecule mimetic at typical doses is unclear, but the conservative position is to avoid

• Sourcing. Research-grade powder is sold from a handful of mostly Russian and Chinese suppliers. Independent third-party testing is rare and product purity varies. If you are using this, third-party COAs (certificates of analysis) and reputation of the supplier matter more than price

• Long-term unknowns. Whether continuous stimulation of hippocampal neurogenesis has any long-term consequences (stem cell pool depletion, off-target gene expression effects, tumour risk) has not been studied in any species at any timescale. Cycling rather than running it continuously is the conservative default